2 results match your criteria: "Oncology Department of Jiangxi Maternal and Child Health Care Hospital[Affiliation]"
Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma.
Cell Div
September 2023
Oncology Department of Jiangxi Maternal and Child Health Care Hospital, No. 318, Bayi Avenue, Nanchang, 330006, Jiangxi, China.
Background: Chemotherapy resistance is a leading cause of treatment failure in cases of cervical adenocarcinoma (ADC), and no effective treatment approach has yet been found. We previously identified the differentially expressed kynureninase (KYNU) mRNA in cervical adenocarcinoma cells (HeLa) and cervical adenocarcinoma cisplatin resistance cells (HeLa/DDP) using gene chips. However, the role and potential mechanism of KYNU in the cisplatin resistance of cervical adenocarcinoma remain unclear.
View Article and Find Full Text PDFThe Therapeutic Value of Adjuvant Chemotherapy after Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer.
Gynecol Obstet Invest
November 2023
Graduate Department of the Medical College of Nanchang University, Nanchang, China.
Objective: The aim of this study was to evaluate the therapeutic value and treatment-related complications of adjuvant chemotherapy after concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC).
Design: The medical records of LACC patients who underwent CCRT were reviewed retrospectively.
Methods: A total of 1,138 patients with LACC who had been treated at our hospital between January 2013 and December 2017 were included in the study and classified into two groups: the CCRT group, comprising 726 patients who had received only CCRT, and the CCRT + adjuvant chemotherapy (ACT) group, comprising 412 patients who had received three cycles of adjuvant chemotherapy after CCRT.